Equities

Sangamo Therapeutics Inc

Sangamo Therapeutics Inc

Actions
  • Price (EUR)2.56
  • Today's Change-0.128 / -4.76%
  • Shares traded25.21k
  • 1 Year change+617.83%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Sangamo Therapeutics Inc had net income fall 34.09% from a loss of 192.28m to a larger loss of 257.83m despite a 58.34% increase in revenues from 111.30m to 176.23m.
Gross margin--
Net profit margin-2,033.68%
Operating margin-2,093.97%
Return on assets-119.44%
Return on equity-194.05%
Return on investment-153.51%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Sangamo Therapeutics Inc fell by 55.24m. However, Cash Flow from Investing totalled 153.53m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 224.84m for operations while cash generated from financing totalled 14.59m.
Cash flow per share-1.30
Price/Cash flow per share--
Book value per share0.1138
Tangible book value per share0.1138
More ▼

Balance sheet in USDView more

Sangamo Therapeutics Inc uses little or no debt in its capital structure.
Current ratio1.03
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.